Messy Excel formulas are more than just an eyesore—they're harder to maintain. Every repeated cell reference and tangled ...

Exact Sciences Corporation stock surged after Abbott Laboratories announces a $21bn acquisition at $105 per share, driven by Exact's cancer diagnostics leadership. Exact Sciences boasts strong revenue ...

Abbott to buy Exact Sciences in $23 billion deal Exact's flagship colorectal cancer test to join Abbott's portfolio Abbott eyes international expansion for Exact's tests Aims for broad reimbursement ...

Abbott Laboratories ABT-0.41%decrease; red down pointing triangle agreed to acquire cancer diagnostics company Exact Sciences EXAS-0.11%decrease; red down pointing triangle in a deal valued at about ...

In January, Exact Sciences CEO Kevin Conroy told us that 2025 was shaping up to be a transformative year for the diagnostics company. Three cancer test launches, multiple study readouts and one $23 ...

Gift Article 10 Remaining As a subscriber, you have 10 articles to gift each month. Gifting allows recipients to access the article for free. Abbott Laboratories agreed to acquire cancer-screening ...

(Reuters) -Abbott will buy cancer test maker Exact Sciences in a deal valued at up to $23 billion, including debt, marking one of its largest purchases in nearly a decade and a bold entry into the ...

North suburban-based Abbott Laboratories announced a $21 billion deal Thursday morning to acquire Exact Sciences, the maker of Cologuard — its largest acquisition in a decade. The deal will allow ...

The pending $23 billion sale of Madison-based Exact Sciences to health care giant Abbott centers on Exact Sciences' flagship product: colorectal cancer test Cologuard. Exact Sciences markets Cologuard ...

ABBOTT PARK, Ill./MADISON, Wis. — Abbott Laboratories, headquartered in north suburban Abbott Park, will acquire Madison, Wisconsin-based Exact Sciences, the companies announced in a news release ...

Exact Sciences (EXAS) will likely need to see over $100 a share in a takeover, according to a William Blair analyst, after an earlier report that Abbott Labs (ABT) is in talks to buy the cancer test ...

IFS and Anthropic have teamed up to introduce Resolve, an AI platform designed to support industrial field workers by interpreting complex data, predicting faults, and streamlining operations, ...